Stay updated on Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial
Sign up to get notified when there's something new on the Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial page.

Latest updates to the Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe Publications section now clarifies that PubMed-sourced publications are auto-filled and linked to the NCT number. It specifies the origin of these entries and how they relate to the study record.SummaryDifference0.1%

- Check19 days agoChange DetectedRemoved the government funding lapse notice from the page, which previously stated that information may not be up to date and that the agency may not respond until appropriations are enacted. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check33 days agoChange DetectedThe Study Details page appears unchanged between the two screenshots; no new or removed information was detected.SummaryDifference0.5%

- Check62 days agoChange DetectedMajor update: announces a funding-related operating status notice and a new version v3.2.0; replaces the earlier v3.1.0 release.SummaryDifference3%

- Check69 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0. The change is limited to the revision label; no core content or critical data appears to be altered.SummaryDifference0.1%

- Check83 days agoChange DetectedUpdated from Revision: v3.0.1 to Revision: v3.0.2; the 'Back to Top' link was removed.SummaryDifference0.2%

Stay in the know with updates to Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial page.